Frontline Mosunetuzumab Shows High Response Rates in Follicular Lymphoma

Published Date: 27 Dec 2024

Promising single-agent efficacy with manageable safety may reshape initial treatment

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Win for Perioperative Durvalumab in Muscle-Invasive Bladder Cancer

2.

investigating radiation oncology applications of artificial general intelligence.

3.

Delay of more than 42 days for breast cancer surgery raises death risk for certain subtypes, study finds

4.

In Biochemically Recurrent Nonmetastatic Prostate Cancer, Apalutamide Presents Its Argument.

5.

Colon cancer and exercise: Can physical activity reprogram genes?


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot